Barinthus Biotherapeutics

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Eight participants achieved HBsAg loss at any time Two participants met criteria for functional cure Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. 15 November 2024 — Oxford, UK — Barinthus Biotherapeutics plc, today announced the most significant data so far from the ongoing Phase 2b HBV003 clinical trial. The data will be…

Barinthus Bio Names Experienced Physician, Leon Hooftman MD, as Chief Medical Officer

Dr Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, haematology, oncology and infectious diseases 1 May 2024 — Oxford, UK — Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, today announced the appointment of Leon…

New partnership aims to advance vaccine against MERS coronavirus

CEPI to invest up to $47m to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500 VTP-500 project with Barinthus Bio and University of Oxford, UK, uses tested ChAdOx1 platform If successful in phase 2 trials, this will progress VTP-500 significantly towards regulatory approval and doses could be rapidly deployed in a clinical trial…

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline. In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well-tolerated in both trials. 10 November 2023 — Oxford, UK — Barinthus Biotherapeutics, formerly Vaccitech, today…

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T-Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity and Cancer

New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data 6 November 2023 — Oxford, UK — Barinthus Biotherapeutics, formerly Vaccitech, a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its phase 2 Hepatitis…